Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth

Rajneesh Pathania, Sabarish Ramachandran, Gurusamy Mariappan, Priyanka Thakur, Huidong Shi, Jeong Hyeon Choi, Santhakumar Manicassamy, Ravindra Kolhe, Puttur D. Prasad, Suash Sharma, Bal L. Lokeshwar, Vadivel Ganapathy, Muthusamy Thangaraju

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Recently, impressive technical advancements have been made in the isolation and validation of mammary stem cells and cancer stem cells (CSC), but the signaling pathways that regulate stem cell self-renewal are largely unknown. Furthermore, CSCs are believed to contribute to chemo- and radioresistance. In this study, we used the MMTV-Neu-Tg mouse mammary tumor model to identify potential new strategies for eliminating CSCs. We found that both luminal progenitor and basal stem cells are susceptible to genetic and epigenetic modifications, which facilitate oncogenic transformation and tumorigenic potential. A combination of the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased the overall survival in this mouse model. RNA-seq analysis of CSCs treated with 5-azacytidine plus butyrate provided evidence that inhibition of chromatin modifiers blocks growth-promoting signaling molecules such as RAD51AP1 and SPC25, which play key roles in DNA damage repair and kinetochore assembly. Moreover, RAD51AP1 and SPC25 were significantly overexpressed in human breast tumor tissues and were associated with reduced overall patient survival. In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.

Original languageEnglish (US)
Pages (from-to)3224-3235
Number of pages12
JournalCancer Research
Volume76
Issue number11
DOIs
StatePublished - Jun 1 2016

Fingerprint

Neoplastic Stem Cells
Epigenomics
Azacitidine
Butyrates
Breast Neoplasms
Breast
Stem Cells
Growth
Neoplastic Cell Transformation
Kinetochores
Histone Deacetylase Inhibitors
Survival
DNA Repair
DNA Damage
Chromatin
RNA
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. / Pathania, Rajneesh; Ramachandran, Sabarish; Mariappan, Gurusamy; Thakur, Priyanka; Shi, Huidong; Choi, Jeong Hyeon; Manicassamy, Santhakumar; Kolhe, Ravindra; Prasad, Puttur D.; Sharma, Suash; Lokeshwar, Bal L.; Ganapathy, Vadivel; Thangaraju, Muthusamy.

In: Cancer Research, Vol. 76, No. 11, 01.06.2016, p. 3224-3235.

Research output: Contribution to journalArticle

@article{136bda256c9b4f01b20fc43bdc685b34,
title = "Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth",
abstract = "Recently, impressive technical advancements have been made in the isolation and validation of mammary stem cells and cancer stem cells (CSC), but the signaling pathways that regulate stem cell self-renewal are largely unknown. Furthermore, CSCs are believed to contribute to chemo- and radioresistance. In this study, we used the MMTV-Neu-Tg mouse mammary tumor model to identify potential new strategies for eliminating CSCs. We found that both luminal progenitor and basal stem cells are susceptible to genetic and epigenetic modifications, which facilitate oncogenic transformation and tumorigenic potential. A combination of the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased the overall survival in this mouse model. RNA-seq analysis of CSCs treated with 5-azacytidine plus butyrate provided evidence that inhibition of chromatin modifiers blocks growth-promoting signaling molecules such as RAD51AP1 and SPC25, which play key roles in DNA damage repair and kinetochore assembly. Moreover, RAD51AP1 and SPC25 were significantly overexpressed in human breast tumor tissues and were associated with reduced overall patient survival. In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.",
author = "Rajneesh Pathania and Sabarish Ramachandran and Gurusamy Mariappan and Priyanka Thakur and Huidong Shi and Choi, {Jeong Hyeon} and Santhakumar Manicassamy and Ravindra Kolhe and Prasad, {Puttur D.} and Suash Sharma and Lokeshwar, {Bal L.} and Vadivel Ganapathy and Muthusamy Thangaraju",
year = "2016",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-15-2249",
language = "English (US)",
volume = "76",
pages = "3224--3235",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth

AU - Pathania, Rajneesh

AU - Ramachandran, Sabarish

AU - Mariappan, Gurusamy

AU - Thakur, Priyanka

AU - Shi, Huidong

AU - Choi, Jeong Hyeon

AU - Manicassamy, Santhakumar

AU - Kolhe, Ravindra

AU - Prasad, Puttur D.

AU - Sharma, Suash

AU - Lokeshwar, Bal L.

AU - Ganapathy, Vadivel

AU - Thangaraju, Muthusamy

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Recently, impressive technical advancements have been made in the isolation and validation of mammary stem cells and cancer stem cells (CSC), but the signaling pathways that regulate stem cell self-renewal are largely unknown. Furthermore, CSCs are believed to contribute to chemo- and radioresistance. In this study, we used the MMTV-Neu-Tg mouse mammary tumor model to identify potential new strategies for eliminating CSCs. We found that both luminal progenitor and basal stem cells are susceptible to genetic and epigenetic modifications, which facilitate oncogenic transformation and tumorigenic potential. A combination of the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased the overall survival in this mouse model. RNA-seq analysis of CSCs treated with 5-azacytidine plus butyrate provided evidence that inhibition of chromatin modifiers blocks growth-promoting signaling molecules such as RAD51AP1 and SPC25, which play key roles in DNA damage repair and kinetochore assembly. Moreover, RAD51AP1 and SPC25 were significantly overexpressed in human breast tumor tissues and were associated with reduced overall patient survival. In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.

AB - Recently, impressive technical advancements have been made in the isolation and validation of mammary stem cells and cancer stem cells (CSC), but the signaling pathways that regulate stem cell self-renewal are largely unknown. Furthermore, CSCs are believed to contribute to chemo- and radioresistance. In this study, we used the MMTV-Neu-Tg mouse mammary tumor model to identify potential new strategies for eliminating CSCs. We found that both luminal progenitor and basal stem cells are susceptible to genetic and epigenetic modifications, which facilitate oncogenic transformation and tumorigenic potential. A combination of the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased the overall survival in this mouse model. RNA-seq analysis of CSCs treated with 5-azacytidine plus butyrate provided evidence that inhibition of chromatin modifiers blocks growth-promoting signaling molecules such as RAD51AP1 and SPC25, which play key roles in DNA damage repair and kinetochore assembly. Moreover, RAD51AP1 and SPC25 were significantly overexpressed in human breast tumor tissues and were associated with reduced overall patient survival. In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84975078260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975078260&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2249

DO - 10.1158/0008-5472.CAN-15-2249

M3 - Article

C2 - 27197203

AN - SCOPUS:84975078260

VL - 76

SP - 3224

EP - 3235

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -